Γ
Content Highlights || Full Agenda
Fireside Chat

11:05 AM

-

11:25 AM

Tools & Tech

From AI protein design to real-world commercial impact: powering the next wave of everyday products

For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning enable the rational creation of enzymes tailored for home care, personal care, and next-generation materials—moving beyond incremental discovery to purpose-built performance under real industrial conditions. Critically, this highlights how AI-driven design is being translated into commercially deployed products at scale with partners and customers.

Fireside Chat

11:05 AM

-

11:25 AM

Tools & Tech

From AI protein design to real-world commercial impact: powering the next wave of everyday products

For more than a century, everyday products - from detergents and shampoos to textiles and packaging - have relied on petrochemicals and harsh industrial processes. Today, AI-driven protein design is opening a radically different path: creating custom enzymes and biomolecules that outperform traditional chemistry while reducing environmental impact. This session explores how advances in computational protein design and machine learning enable the rational creation of enzymes tailored for home care, personal care, and next-generation materials—moving beyond incremental discovery to purpose-built performance under real industrial conditions. Critically, this highlights how AI-driven design is being translated into commercially deployed products at scale with partners and customers.

SynBioBeta is where the people building with biology meet the people funding, buying, and partnering with them. If you're raising capital, scouting the next wave of AIxBIO companies, or looking for your next technology partner - the people you need are here for three days.

The startups on stage this year are building programmable RNA medicines, virtual cell models, AI-designed enzymes, and proteins that replace sugar - alongside GSK, Sanofi, Novo Nordisk, Eli Lilly, J&J, Mars, Apple, Google, NVIDIA, Unilever, and P&G.

Watching where the partnerships form and which technologies the biggest players are actually evaluating is something you can't get from a report or a webinar. And our 1:1 Partnering App lets you book meetings before you arrive.

“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”
“SynBioBeta is a who’s who of AI and biology.
This is where the future is being built, so don't miss it”

Eric Schmidt

Former CEO

"For every single fund at Boom Capital, one of our best companies has come directly from SynBioBeta. I met Mammoth Bio at SynBioBeta, and I met Nabla Bio at SynBioBeta."

Celestine Schnugg

Founder

"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."
"Nabla was accelerated into existence because of SynBioBeta. I met Seth Bannon from 50 Years, Cee Cee Schnugg from Boom Capital, and others from Y Combinator there, and those same people seeded Nabla. The vibe, leverage, and energy at SynBioBeta are unreal."

Surge Biswas

Founder

"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."
"Our Series A came together because of a little bit of SynBioBeta magic. I’ve been attending for a decade and it’s been inspiring to watch the field evolve from a lot of hopes and dreams to real products and applications."

Jacob Glanville

Founder & CEO

"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."
"I met Algen at SynBioBeta and later invested in the company. It’s exactly the kind of connection that makes the community so valuable."

Bill Tai

Co-founder

"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."
"At SynBioBeta I met the team at Biomatter, an AI-driven enzyme design company. The environment made it easy to start a real conversation. That conversation turned into a collaboration to improve one of our enzymes. We're now exploring entirely new performance possibilities together."

Luis Cascao-Pereira

Head of Digital Biology

"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."
"Every time I attend SynBioBeta, I walk away with something transformative – a new investor, a fantastic hire, or an idea that changes how we work. It’s a community unlike any other."

Ola Wlodek

CEO

Who’s Coming to SynBioBeta?

And the BD and R&D Leads
That Will Be Your Customers and Partners: